Natco Pharma Limited has informed the Exchange about Transcript
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma reported record FY25 consolidated revenue of INR4,784 crore (up 16% YoY) and net profit of INR1,883.4 crore (up 36% YoY), its highest ever. Q4 FY25 revenue was INR1,287.3 crore with profit of INR406 crore, though the quarter included a INR50 crore impairment in the Crop Health Science (Agrochem) business and a INR25 crore chargeback in the US subsidiary. For FY26, management has guided for a ~20% revenue dip and ~30% PAT decline, citing US pricing pressure, geopolitical uncertainty, and higher R&D spend (targeting ~INR400 crore). The company holds INR3,500 crore in cash and is actively pursuing acquisitions, including a potential US manufacturing/distribution asset. Key pipeline catalysts include a Risdiplam court order expected by July–August 2025 and a Semaglutide launch targeted by year-end FY26.
Despite a record FY25, the cautious FY26 guidance signals a tough year ahead, particularly from US business headwinds and Revlimid erosion, which may weigh on near-term stock sentiment. However, the strong cash pile of INR3,500 crore supports growth via R&D and acquisitions, while pipeline wins in Risdiplam and Semaglutide remain key upside catalysts for shareholders.